CLEC7A and neoplasm: Furthermore, patients with higher frequencies of tumor-infiltrating Dectin-1+ cDC2s were 6 times more likely to undergo worse outcome, as indicated by shorter progression-free survival (PFS), than patients with low frequencies (HR = 6.15 and P-value = 0.037; Figure 6D).